A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Recruiting · NCT07300969 · Interventional (participants receive a specific treatment) · Lead sponsor: Draig Therapeutics Ltd
View the official record on ClinicalTrials.gov →Interventions studied
DT-101Placebo
What this trial is about
The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent
- Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent.
- Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022).
Exclusion criteria
- Pregnant or breastfeeding or plans to become pregnant during the study.
- Unstable medical condition or unstable chronic disease.
- Significant neurological abnormality.
- History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening.
- History of seizure.
- In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.
Where it is running
43 locations listed across 13 US states.
- Draig Clinical Site - Bentonville, Arkansas, United States
- Draig Clinical Site - Little Rock, Arkansas, United States
- Draig Clinical Site - Oceanside, California, United States
- Draig Clinical Site - San Diego, California, United States
- Draig Clinical Site - Torrance, California, United States
- Draig Clinical Site - Miami, Florida, United States
- Draig Clinical Site - New Port Richey, Florida, United States
- Draig Clinical Site - Orlando, Florida, United States
- Draig Clinical Site - Atlanta, Georgia, United States
- Draig Clinical Site - Decatur, Georgia, United States
- Draig Clinical Site - Gaithersburg, Maryland, United States
- Draig Clinical Site - Watertown, Massachusetts, United States
- Draig Clinical Site - Flowood, Mississippi, United States
- Draig Clinical Site - Las Vegas, Nevada, United States
- Draig Clinical Site - Marlton, New Jersey, United States
- Draig Clinical Site - New York, New York, United States
- Draig Clinical Site - Media, Pennsylvania, United States
- Draig Clinical Site - Austin, Texas, United States
- Draig Clinical Site - Austin, Texas, United States
- Draig Clinical Site - DeSoto, Texas, United States
- Draig Clinical Site - Richardson, Texas, United States
- Draig Clinical Site - Wichita Falls, Texas, United States
- Draig Clinical Site - Bellevue, Washington, United States
- Draig Clinical Site - Chester, United Kingdom
- Draig Clinical Site - Eastbourne, United Kingdom
- Draig Clinical Site - Gdansk, Poland
- Draig Clinical Site - Glasgow, United Kingdom
- Draig Clinical Site - Katowice, Poland
- Draig Clinical Site - Kazanlak, Bulgaria
- Draig Clinical Site - London, United Kingdom
- Draig Clinical Site - London, United Kingdom
- Draig Clinical Site - Nottingham, United Kingdom
- Draig Clinical Site - Ostrava, Czechia
- Draig Clinical Site - Oxford, United Kingdom
- Draig Clinical Site - Plovdiv, Bulgaria
- Draig Clinical Site - Poznan, Poland
- Draig Clinical Site - Prague, Czechia
- Draig Clinical Site - Sofia, Bulgaria
- Draig Clinical Site - Sofia, Bulgaria
- Draig Clinical Site - Sofia, Bulgaria
- Draig Clinical Site - Sofia, Bulgaria
- Draig Clinical Site - Vratsa, Bulgaria
- Draig Clinical Site - Říčany, Czechia